Thomas Schinecker, Roche CEO (Betty Laura Zapata/Bloomberg via Getty Images)
October 23, 2024 01:54 PM EDT
Pharma
Manufacturing

Al­low­ing No­vo-Catal­ent deal to close would be ‘wrong de­ci­sion’ by an­titrust au­thor­i­ties, Roche CEO says

Ayisha Sharma

News Reporter

An­titrust reg­u­la­tors shouldn’t clear No­vo Hold­ings’ planned ac­qui­si­tion of Catal­ent, Roche CEO Thomas Schi­neck­er said Wednes­day, adding to the pres­sure that in­dus­try com­peti­tors ap­pear to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times